TORONTO, Dec. 15 /CNW/ - Bradmer Pharmaceuticals Inc., a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, announced today that it has received the guidance of the
United States Food and Drug Administration with regard to a multi-center
Phase III trial presented in an End of Phase II meeting with the Agency. The
face to face meeting was held at the FDA on November 14, 2006 and minutes of
the meeting were received December 14, 2006.
